共 50 条
- [21] ONCE-DAILY VIBEGRON 75 MG IMPROVES QUALITY-OF-LIFE AND INCONTINENCE EFFICACY ENDPOINTS IN PATIENTS WITH OVERACTIVE BLADDER: DOUBLE-BLIND 52-WEEK RESULTS FROM AN EXTENSION STUDY OF THE EMPOWUR INTERNATIONAL PHASE 3 TRIALNEUROUROLOGY AND URODYNAMICS, 2020, 39 : S330 - S331Staskin, D.Frankel, J.Varano, S.Shortino, D.Jankowich, R.Mudd, Jr P.
- [22] Efficacy of novel β3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 studyINTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (03) : 369 - 375Yoshida, MasakiTakeda, MasayukiGotoh, MomokazuYokoyama, OsamuKakizaki, HidehiroTakahashi, SatoruMasumori, NaoyaNagai, ShinjiHashimoto, KeitaMinemura, Kazuyoshi
- [23] A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testingEUROPEAN UROLOGY, 1998, 33 (05) : 481 - 488de Mey, CMichel, MCMcEwen, JMoreland, T
- [24] The Effect of Caffeinated Versus Decaffeinated Drinks on Overactive Bladder A Double-Blind, Randomized, Crossover StudyJOURNAL OF WOUND OSTOMY AND CONTINENCE NURSING, 2014, 41 (04) : 371 - 378Wells, Mandy J.Jamieson, KatharineMarkham, Tamsyn C. W.Green, Sue M.Fader, Mandy J.
- [25] A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People With Overactive BladderFUTURE CARDIOLOGY, 2023, : 363 - 370Weber, Michael A.Lucioni, AlvaroGregg, Steven G.Owens-Grillo, Janet
- [26] Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)EUROPEAN UROLOGY, 2015, 67 (03) : 577 - 588Abrams, PaulKelleher, ConStaskin, DavidRechberger, TomaszKay, RichardMartina, ReynaldoNewgreen, DonaldPaireddy, Ashavan Maanen, RobRidder, Arwin
- [27] Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR) COMMENTJOURNAL OF UROLOGY, 2021, 205 (05): : 1428 - 1429Chapple, C. R.
- [28] EFFICACY AND SAFETY OF COMBINATION OF TOLTERODINE AND PILOCARPINE IN OVERACTIVE BLADDER PATIENTS: A RANDOMIZED DOUBLE-BLIND MULTICENTER PHASE 3 STUDYNEUROUROLOGY AND URODYNAMICS, 2017, 36 : S45 - S46Lee, K.Ko, K. J.Yoon, S. J.Kim, S. W.Kim, S.Seo, J. T.Choo, M.Lee, S. W.
- [29] Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR) REPLYJOURNAL OF UROLOGY, 2021, 205 (05): : 1429 - 1429不详
- [30] VIBEGRON FOR THE TREATMENT OF PATIENTS WITH DRY OVERACTIVE BLADDER: A SUBGROUP ANALYSIS FROM THE EMPOWUR TRIALJOURNAL OF UROLOGY, 2021, 206 : E1107 - E1108Staskin, DavidFrankel, JeffreyVarano, SusannKennelly, MichaelNewman, Diane K.Rosenberg, Matt T.Shortino, DeniseJankowich, Rachael A.Mudd, Paul N., Jr.